• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.

作者信息

Garcet Sandra, Nograles Kristine, Correa da Rosa Joel, Schafer Peter H, Krueger James G

机构信息

Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY.

Clinical Research and Development, Celgene Corporation, Summit, NJ.

出版信息

J Allergy Clin Immunol. 2018 Sep;142(3):1010-1013.e6. doi: 10.1016/j.jaci.2018.05.039. Epub 2018 Jun 21.

DOI:10.1016/j.jaci.2018.05.039
PMID:29936103
Abstract
摘要

相似文献

1
Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.银屑病患者中协同细胞因子效应作为阿普斯特反应预测指标
J Allergy Clin Immunol. 2018 Sep;142(3):1010-1013.e6. doi: 10.1016/j.jaci.2018.05.039. Epub 2018 Jun 21.
2
Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.阿普司特治疗中度至重度银屑病的真实世界单中心经验。
Clin Exp Dermatol. 2017 Aug;42(6):675-676. doi: 10.1111/ced.13150. Epub 2017 Jun 16.
3
Apremilast for the management of moderate to severe plaque psoriasis.阿普米拉斯用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2017 Apr;10(4):349-360. doi: 10.1080/17512433.2017.1293519. Epub 2017 Feb 17.
4
Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.阿普米司特治疗银屑病临床疗效的潜在机制
J Drugs Dermatol. 2018 Aug 1;17(8):835-840.
5
Chronic tearing induced by apremilast.阿普斯特诱发的慢性流泪。
Ann Allergy Asthma Immunol. 2018 Sep;121(3):375. doi: 10.1016/j.anai.2018.06.027. Epub 2018 Jun 30.
6
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.评估在2019冠状病毒病大流行期间使用阿普米拉斯治疗银屑病的风险。
J Drugs Dermatol. 2021 May 1;20(5):582-583. doi: 10.36849/JDD.5730.
7
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.阿普司特，一种口服磷酸二酯酶4抑制剂，用于治疗日本中重度斑块状银屑病患者：2b期随机对照试验的疗效、安全性和耐受性结果
J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9.
8
Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.磷酸二酯酶4抑制剂阿普司特可改善银屑病患者的胰岛素抵抗。
J Dermatol. 2022 Apr;49(4):e125-e126. doi: 10.1111/1346-8138.16286. Epub 2021 Dec 27.
9
Apremilast in the treatment of psoriasis and psoriatic arthritis.阿普司特治疗银屑病和银屑病关节炎。
Skin Therapy Lett. 2015 Sep-Oct;20(5):1-6.
10
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.阿普米司特：用于银屑病和银屑病关节炎的治疗。
Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1.

引用本文的文献

1
Apremilast Decreased Proinflammatory Cytokines and Subsequently Increased Inhibitory ones in Psoriasis: A Prospective Cohort Study.阿普司特降低银屑病中促炎细胞因子水平并随后增加抑制性细胞因子水平：一项前瞻性队列研究
Acta Derm Venereol. 2024 May 13;104:adv37555. doi: 10.2340/actadv.v104.37555.
2
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.阿普米司特治疗日本掌跖脓疱病患者的疗效和安全性：来自一项 2 期、随机、安慰剂对照研究的结果。
Am J Clin Dermatol. 2023 Sep;24(5):837-847. doi: 10.1007/s40257-023-00788-2. Epub 2023 May 26.
3
Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.
药物组学在银屑病中的应用：迈向个体化医学之路。
Int J Mol Sci. 2023 Apr 11;24(8):7090. doi: 10.3390/ijms24087090.
4
Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.布罗达umab 阻断白细胞介素-17RA 可减少化脓性汗腺炎皮肤和血清中的炎症通路。
Br J Dermatol. 2022 Aug;187(2):223-233. doi: 10.1111/bjd.21060. Epub 2022 Jun 2.
5
Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo.小分子变构 RORγt 抑制剂阻断体内 Th17 依赖性炎症及相关基因表达。
PLoS One. 2021 Nov 9;16(11):e0248034. doi: 10.1371/journal.pone.0248034. eCollection 2021.
6
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.在中重度银屑病日本患者中，阿普司特的群体药代动力学和暴露-反应分析。
J Dermatol. 2021 Nov;48(11):1652-1664. doi: 10.1111/1346-8138.16068. Epub 2021 Aug 15.
7
Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity.银屑病的分子发病机制及反映疾病活动的生物标志物
J Clin Med. 2021 Jul 21;10(15):3199. doi: 10.3390/jcm10153199.
8
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics.银屑病的关键信号通路：来自抗银屑病治疗的最新见解
Psoriasis (Auckl). 2021 Jun 29;11:83-97. doi: 10.2147/PTT.S294173. eCollection 2021.
9
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.Janus 激酶抑制剂和磷酸二酯酶-4 抑制剂对银屑病患者皮肤和血浆细胞因子水平的影响。
Bull Exp Biol Med. 2021 May;171(2):208-211. doi: 10.1007/s10517-021-05196-2. Epub 2021 Jun 26.
10
Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial.阿普米司特治疗日本中重度斑块状银屑病的药效学分析：一项 2b 期随机试验结果。
J Dermatol. 2021 Jan;48(1):80-84. doi: 10.1111/1346-8138.15596. Epub 2020 Sep 10.